Rapport Therapeutics, Inc.
RAPP
Positions held
Your positionsRAPP isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Rapport Therapeutics operates in the biotechnology sector, which is known for its potential to revolutionize healthcare through innovative therapies and treatments.
- The company's market cap stands at approximately $1.49 billion, indicating a significant valuation in the biotech space.
- Despite current challenges, the target mean price for RAPP is $63.04, suggesting a potential upside from its current trading levels.
- Rapport Therapeutics has reported a revenue decline of 100% compared to the prior quarter, with revenue dropping from $20 million to $0.
- The company has a strong sell score of -16.00, reflecting negative trends and bearish indicators in its market performance.
- In the last year, Rapport's net income has consistently been negative, totaling -111.483 million in 2025, -78.307 million in 2024, and -34.786 million in 2023.
Fundamentals
| Market cap | $1.43B | Enterprise value | $1.01B | Trailing P/E | — | Forward P/E | -5.87 |
| PEG | — | Price / book | 3.38 | Beta | 1.22 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | -109.4% | Operating margin | -7.7% |
| Profit margin | 0.0% | ROE | -40.0% | ROA | -25.8% | Debt / equity | 0.02 |
| Current ratio | 15.72 | Free cash flow | -$56.02M | Analyst recommendation | strong_buy | Mean target | $63.04 |
| 52w high | $52.93 | 52w low | $23.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $20.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | -121.1% | — | — | — |
| Net income | -$56.6M | -$19.9M | -$33.8M | -$26.9M | -$26.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.8M | -$24.2M | -$38.5M | -$30.0M | -$29.5M |
- Revenue -100% vs prior quarter ($0 vs $20M).
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$111M | -$78.3M | -$34.8M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$125M | -$83.1M | -$36.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target
2026-09-23 · The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
2026-09-23 · The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
2026-09-22 · 4 Biotech Stocks With Key Clinical Readouts Expected This Fall
2026-09-02 · Rapport Therapeutics to Participate in Upcoming Investor Conferences
2026-08-24 · Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
2026-08-05 · Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
2026-07-28 · William Blair Initiates Rapport Therapeutics at Outperform
Price (daily)
Full chart · RSI · MACD · patterns